Published in Prog Neuropsychopharmacol Biol Psychiatry on September 26, 2007
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 2.15
So depression is an inflammatory disease, but where does the inflammation come from? BMC Med (2013) 2.02
Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med (2013) 1.78
Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci (2009) 1.58
Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology (2011) 1.44
Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry (2010) 1.37
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumtol (2011) 1.26
Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis (2009) 1.22
Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry (2012) 1.22
Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry (2012) 1.17
Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun (2015) 1.10
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med (2013) 1.03
The inflammation hypothesis in geriatric depression. Int J Geriatr Psychiatry (2011) 1.01
Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). J Clin Psychiatry (2014) 0.99
A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry (2016) 0.99
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain Behav Immun (2013) 0.98
Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol (2010) 0.97
Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit (2011) 0.96
Treating depression and depression-like behavior with physical activity: an immune perspective. Front Psychiatry (2013) 0.95
The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatry (2013) 0.91
Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry (2015) 0.90
Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol (2014) 0.89
Optimizing the Exercise Prescription for Depression: The Search for Biomarkers of Response. Curr Opin Psychol (2015) 0.88
Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder. Psychiatry Investig (2013) 0.84
Depressive symptoms during rehabilitation period predict poor outcome of lumbar spinal stenosis surgery: a two-year perspective. BMC Musculoskelet Disord (2010) 0.84
Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl) (2015) 0.84
Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology (2014) 0.83
Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress (2016) 0.83
Circulating microRNA-144-5p is associated with depressive disorders. Clin Epigenetics (2015) 0.82
A Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-naive Depressed Women: A Pilot Study. Iran J Pharm Res (2015) 0.81
Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. J Psychosom Res (2011) 0.81
Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? Curr Neuropharmacol (2012) 0.81
DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl Psychiatry (2013) 0.81
The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res (2015) 0.80
Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience. Neuropsychopharmacology (2016) 0.80
Immunity, aging, and geriatric depression. Psychiatr Clin North Am (2011) 0.80
The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Curr Neuropharmacol (2015) 0.79
Adolescent-Onset Depression: Are Obesity and Inflammation Developmental Mechanisms or Outcomes? Child Psychiatry Hum Dev (2015) 0.79
The mechanisms by which antidepressants may reduce coronary heart disease risk. BMC Cardiovasc Disord (2015) 0.77
Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report. J Med Case Rep (2010) 0.76
Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response. Psychiatry Investig (2016) 0.75
Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study. Neuropsychiatr Dis Treat (2015) 0.75
Anti-inflammatory Effect of Amitriptyline on Ulcerative Colitis in Normal and Reserpine-Induced Depressed Rats. Iran J Pharm Res (2016) 0.75
Leukocyte telomere length predicts SSRI response in major depressive disorder: A preliminary report. Mol Neuropsychiatry (2016) 0.75
Beneficial Effects of Maprotiline in a Murine Model of Colitis in Normal and Reserpinised Depressed Rats. Int Sch Res Notices (2014) 0.75
Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. Curr Neuropharmacol (2016) 0.75
Effect of Ondansetron, a 5-HT(3) receptor antagonist, on fatigue in 2 veterans with hepatitis C. Prim Care Companion J Clin Psychiatry (2009) 0.75
Sirukumab: A Potential Treatment for Mood Disorders? Adv Ther (2016) 0.75
Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression. J Renal Inj Prev (2016) 0.75
Depression contributed an unsatisfactory surgery outcome among the posterior decompression of the cervical spondylotic myelopathy patients: a prospective clinical study. Neurol Sci (2014) 0.75
The renin-angiotensin system: a possible new target for depression. BMC Med (2017) 0.75
Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharmacol (2017) 0.75
Randomized trial of a meditation-based stress reduction program and cognitive behavior therapy in generalized social anxiety disorder. Behav Res Ther (2007) 1.51
Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. Biol Psychiatry (2010) 1.46
Sleep quality and more common sleep-related problems in medical students. Sleep Med (2005) 1.35
Symptoms of anxiety and depression in Estonian medical students with sleep problems. Depress Anxiety (2006) 1.19
Unedited in vivo detection and quantification of γ-aminobutyric acid in the occipital cortex using short-TE MRS at 3 T. NMR Biomed (2013) 0.99
Symptoms of depression in the Estonian population: prevalence, sociodemographic correlates and social adjustment. J Affect Disord (2004) 0.99
Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatr Genet (2005) 0.96
Serotonin function in panic disorder: important, but why? Neuropsychopharmacology (2006) 0.93
Gender differences in brain serotonin transporter availability in panic disorder. J Psychopharmacol (2010) 0.89
Association of limbic system-associated membrane protein (LSAMP) to male completed suicide. BMC Med Genet (2008) 0.89
Associations between serotonin-related gene polymorphisms and panic disorder. Int J Neuropsychopharmacol (2005) 0.87
CCK-B receptor gene and response to cholecystokinin-tetrapeptide in healthy volunteers. Peptides (2012) 0.86
Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res (2004) 0.86
Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. Neurosci Lett (2006) 0.86
Common variations in 4p locus are related to male completed suicide. Neuromolecular Med (2008) 0.84
Diagnostic stability over 2 years in patients with acute and transient psychotic disorders. Nord J Psychiatry (2011) 0.84
Analysis of SNP profiles in patients with major depressive disorder. Int J Neuropsychopharmacol (2005) 0.83
Myotonometry demonstrates changes of lingual musculature in obstructive sleep apnoea. Eur Arch Otorhinolaryngol (2002) 0.81
Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina (Kaunas) (2009) 0.81
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol (2009) 0.80
Polymorphisms in the interleukin-10 gene cluster are possibly involved in the increased risk for major depressive disorder. BMC Med Genet (2008) 0.80
Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers. World J Biol Psychiatry (2004) 0.79
Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. J Psychopharmacol (2013) 0.79
Thyroid autoimmunity and treatment response to escitalopram in major depression. Nord J Psychiatry (2010) 0.79
Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers. Neurosci Lett (2008) 0.79
A survey of parentally reported sleep health disorders in Estonian 8-9 year old children. BMC Pediatr (2013) 0.79
Interleukin 10 family gene polymorphisms are not associated with major depressive disorder and panic disorder phenotypes. J Psychiatr Res (2009) 0.79
Citalopram challenge in social anxiety disorder. Int J Neuropsychopharmacol (2004) 0.78
Neuroimaging of serotonin system in anxiety disorders. Curr Pharm Des (2012) 0.78
Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. Psychopharmacology (Berl) (2006) 0.78
Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) (2002) 0.78
Personality traits measured by the Swedish universities Scales of Personality: factor structure and position within the five-factor model in an Estonian sample. Nord J Psychiatry (2009) 0.78
The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J Psychopharmacol (2004) 0.78
Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. Int J Neuropsychopharmacol (2004) 0.78
Variation in tryptophan hydroxylase-2 gene is not associated to male completed suicide in Estonian population. Neurosci Lett (2009) 0.78
Evaluation of personality traits in panic disorder using Swedish universities Scales of Personality. J Anxiety Disord (2010) 0.78
Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study. J Clin Psychiatry (2009) 0.78
Genetic factors in anxiety disorders. Mod Trends Pharmacopsychiatri (2013) 0.78
Growth hormone, cortisol and prolactin responses to physical exercise: higher prolactin response in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.77
Help-seeking for emotional problems in major depression : findings of the 2006 Estonian health survey. Community Ment Health J (2012) 0.77
SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci (2004) 0.77
Obstructive sleep apnea and ageing Myotonometry demonstrates changes in the soft palate and tongue while awake. Pathophysiology (2004) 0.77
Manifesto for a European anxiety disorders research network. Eur Neuropsychopharmacol (2010) 0.77
Effects of acute cholecystokinin infusion on hemispheric EEG asymmetry and coherence in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.76
The role of IL-2 and soluble IL-2R in depression and antidepressant response. Curr Opin Investig Drugs (2009) 0.76
Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers. Psychiatry Res (2010) 0.76
The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers. Eur Neuropsychopharmacol (2012) 0.75
Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample. Ann Gen Psychiatry (2013) 0.75
Acute cholecystokinin effects on event-related potentials in healthy volunteers. Hum Psychopharmacol (2002) 0.75
Peripheral gene expression profiling of CCK-4-induced panic in healthy subjects. Am J Med Genet B Neuropsychiatr Genet (2010) 0.75
Tryptophan research in panic disorder. Int J Tryptophan Res (2008) 0.75
The past and the present of Estonian psychiatry. Nord J Psychiatry (2010) 0.75
Obstructive sleep apnea syndrome (OSAS): Pathophysiology in Estonians. Pathophysiology (2010) 0.75